Mean survival gain is a better metric for pricing new cancer drugs - STAT

Mean survival gain is a better metric for pricing new cancer drugs - STAT

Opinion: Accounting for hope: using ‘mean survival gain’ to price new cancer drugs

By ALICE CHEN AND DANA GOLDMAN

ADOBE

Using mean survival gain instead of median survival gain in pricing decisions for new cancer therapies is a better way to account for their value.

READ MORE